Date: 2014-06-10
Type of information: Clinical research agreement
Compound: ARGX-110
Company: Argen-X (The Netherlands-Belgium) The Leukemia & Lymphoma Society
Therapeutic area: Rare diseases - Cancer - Oncology
Type agreement: clinical research
Action mechanism: ARGX-110 is a SIMPLE antibody™ targeting CD70, an immune checkpoint target involved in hematological malignancies (lymphomas and leukemias), several solid tumors and autoimmune diseases. ARGX-110 works in three ways: i) blocks growth of tumor cells, ii) kills cancer cells and iii) activates the patients’ immune system against the tumor.
Disease: refractory Waldenström’s macroglobulinemia
Details: * On June 10, 2014, arGEN-X, a clinical stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, announced it has entered into a partnership with The Leukemia & Lymphoma Society (LLS) in which both parties will contribute to the funding of a Phase 2 clinical study of ARGX-110, in patients with refractory Waldenström’s macroglobulinemia (WM).arGEN-X plans to submit an Investigational New Drug (IND) application with the FDA in the second half of 2014. The study is expected to begin in the second half of 2014, and will be led by Dr. Steven P. Treon, MD, PhD, Director of the Bing Center for Waldenström’s macroglobulinemia at Harvard Medical School (Cambridge, MA, USA).
Financial terms: Under the agreement, both parties will contribute funding, of up to $2.2 million and totaling $4.5 million, with LLS funding coming through its Therapy Acceleration Program (TAP), a strategic initiative to speed the development of therapies that have the potential to change the standard of care for patients with hematological cancers.
Latest news:
